Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion’s US subsidiary (Celltrion USA, Inc.) has finalized the expected acquisition date of December 31, 2025, for its 100% equity purchase of Imclone Systems LLC to establish a US API manufacturing base.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Decision on Acquisition of Shares and Equity Securities of Other Corporation (Voluntary Disclosure – Major Management Matters of Subsidiary) (Correction)
- Original Filing & Correction Date: September 23, 2025 / December 11, 2025
- Reason for Correction: Confirmation and update of the expected acquisition date
- Key Corrected Item:
- Expected Acquisition Date: (Before) Unconfirmed → (After) December 31, 2025
- Acquisition Transaction Overview:
- Acquiring Subsidiary: Celltrion USA, Inc. (CEO: Bon-Joong Kim, 100% owned)
- Target Entity: Imclone Systems LLC (US-based pharmaceutical manufacturing LLC)
- Counterparty: Imclone Systems Holdings, Inc. (Subsidiary of Eli Lilly and Company / Eli Lilly co-signed as guarantor)
- Acquisition Amount: KRW 460,020,000,000 (approx. KRW 460.0B / USD 330,000,000, applied exchange rate: USD/KRW 1,394.00)
- Acquisition-to-Assets Ratio: 2.18% (Based on Celltrion’s FY2024 consolidated total assets of KRW 21,055,222,437,706)
- Post-Acquisition Shareholding: 100% (Cash acquisition)
- Purpose of Acquisition: Establishing a local API manufacturing system in the US
- Subsidiary Approval Date: September 20, 2025 (Date of CEO approval at Celltrion USA, Inc.)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Acquisition Completion on December 31, 2025 and API Facility Integration
This corrected disclosure confirms December 31, 2025, as the finalized acquisition date for Celltrion USA’s purchase of Imclone Systems LLC from Eli Lilly Group, making it important to monitor the closing of the transaction on the scheduled date. Tracking the completion of payment and asset transfer ensures verification of the establishment of US local manufacturing operations. Transaction completion and asset details can be verified through upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports) or subsequent regulatory disclosures.
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please
